MUMBAI, INDIA: Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05% (Emulsion Formulation), a generic version of Olux®1‐E Foam, 0.05%, of Mylan Pharmaceuticals Inc. According to IQVIATM sales data forthe 12 month period ending July 2019, the Olux®‐E Foam, 0.05%…
Search Results for: FDA Approval
Lonza expands Bioconjugation facility and announces approval of third commercial ADC
BASEL, SWITZERLAND: Lonza has announced the start of expansion to its bioconjugation facility in Visp, Switzerland together with the successful commercial approval of a third antibody-drug-conjugate (ADC) produced at the site. Building on 12 years of experience in the exacting bioconjugation space, Lonza’s expansion will meet the development and manufacturing needs of pharma and biotech…
GSK signals confidence with robust Q2 as specialty medicines surge
Operating profit up 33% as strong product mix and R&D drive gains GSK Plc reported another solid quarter in Q2 2025, underscoring its trajectory toward the top end of its full-year guidance. Bolstered by strong growth in Specialty Medicines and Vaccines, the British pharmaceutical giant posted total revenues of £8.0 billion, up 6% at constant…
Ondine Biomedical eyes US market expansion
LONDON: Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial therapies, announced significant milestones in its 2024 annual report, positioning the company for accelerated growth in 2025 and beyond. Key achievements include robust commercial expansion, strategic partnerships and the launch of a pivotal Phase 3 clinical trial in the U.S. Commercial and Clinical Momentum …
NeuroScientific to acquire stem cell technology for Crohn’s disease treatment
PERTH: NeuroScientific Biopharmaceuticals Ltd. (ASX:NSB) announced plans to acquire StemSmart™, a patented stem cell technology from Isopogen WA Ltd., aimed at developing treatments for immune-mediated inflammatory disorders, including refractory Crohn’s disease. The acquisition, subject to shareholder and regulatory approvals, includes binding agreements with key Isopogen shareholders holding 51.4% of the company’s shares. NeuroScientific will issue…
Alcon acquires majority stake in Aurion Biotech
Alcon (SIX/NYSE: ALC), the global leader in eye care, announced today its acquisition of a majority interest in Aurion Biotech, Inc., a clinical-stage company developing advanced cell therapies for treating eye diseases. The move aims to advance Aurion’s promising allogeneic cell therapy asset, AURN001, into Phase 3 trials for corneal edema secondary to corneal endothelial disease later…
RUA Life Sciences has acquired Analytic Biosurgical Solutions (Abiss)
LONDON: RUA Life Sciences (AIM: RUA) has acquired the entire issued share capital of Analytic Biosurgical Solutions SAS, for a cash consideration of €80,000 from the French liquidator of IPSA SAS, the former parent company of Abiss. The acquisition will be funded from the Company’s existing cash resources and will be paid in full on…
HoneyNaps secures a $11.6 million Series B investment
BOSTON: HoneyNaps, an industry-leading South Korean company in artificial intelligence (AI) sleep data analysis, has closed its series B round of funding, securing $11.6 million. The series B funding is a successful achievement, nearly three times the $3.9 million raised through series A funding back in 2021. With the listing contract signed with Korea Investment…
ThinkSono secures £2.1M in oversubscribed funding to advance AI ultrasound technology
ThinkSono has successfully closed an oversubscribed funding round, raising £2.1 million. The round, led by id4 ventures and supported by several key investors, brings the company’s total funding to £5 million. This capital injection will fuel ThinkSono’s mission to transform patient care globally with its AI ultrasound guidance solutions. Concurrently, ThinkSono has earned the Class…
Johnson & Johnson MedTech acquires Laminar Inc. for an upfront $400 million
NEW BRUNSWICK: Johnson & Johnson MedTech, a division of Johnson & Johnson that focuses on medical intervention solutions, announced today that it has completed the acquisition of Laminar Inc., a privately-held medical device company that specializes in eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). The deal was worth $400…
Artrya CEO outlines plans to launch AI-powered heart disease solution in US and Australia
SYDNEY, AUSTRALIA: Artrya Limited, a company that develops artificial intelligence (AI) solutions for heart disease diagnosis and treatment, has announced its progress and goals for the next fiscal year. The company’s CEO, Mathew Regan, said he has focused on three key areas: launching Salix, its flagship product, in the US market; commercializing Salix in Australia…
Inari Medical to acquire LimFlow for up to $415 million
Inari Medical, a company that develops devices for venous and other diseases, has agreed to buy LimFlow, a company that offers a minimally-invasive solution for patients with severe peripheral artery disease who face leg amputation. The deal is worth up to $415 million and is expected to close by the end of 2023. LimFlow’s technology,…